Achieving Lean Processing With Single-Use Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Achieving Lean Processing With Single-Use Systems


Pharmaceutical Technology Europe


The effectiveness of the technologytransfer process is critical to maintaining product quality and decreasing time-to-market. Using different systems from different vendors can impede transfer and force processes developed at one scale to be recreated and re-optimised at other scales; for example, a vendor may not be able to offer its solution at all scales from process development to manufacturing, in which case the client would be forced to buy products and technologies from multiple vendors that may not be fully compatible with one another. Differences in product claims and shelf life from multiple vendors can also impact the implementation of single-use technology during technology transfer.

Using replicable, modular single-use systems, however, can facilitate cost-effective and timely technology transfer across multiple sites and different scales because the same product technology platform, same contact materials and product claims make the qualification process easier.

Impact on the bottom line

Single-use systems can reduce materials usage by as much as 20%. They can also reduce the number of parts that need to be maintained. With each new catalog number incurring a cost of up to approximately €837 to maintain it annually in an ERP system, the reduction represents an important cost saving.

Optimising tangential flow filtration

Tangential flow filtration (TFF) can rapidly and effectively separate and purify biomolecules. Employing single-use systems in this area can improve product yield, quality and purity. The first step in TFF process development is to define what the process must achieve and what goals must be met. Understanding these objectives will aid selection of the appropriate unit operation and operating parameters. Important process objectives to define are:

  • final product concentration
  • feed volume reduction
  • extent of buffer exchange
  • contaminant removal specification.

Next, it is important to identify and quantify any criteria by which the success of the operation will be measured. The primary goals for successful protein processing are:

  • high product yield
  • high product quality (or activity)
  • high product purity
  • controlled bioburden and endotoxin.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here